Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Healthcare
Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc
Bullboard Posts
User Avatar Image
(0)
•••
Comment by anythingon Dec 17, 2010 8:37am
541 Views
Post# 17860877

RE: RE: my only frustration

RE: RE: my only frustration
I made a few pesos on this one but I share your pain - their press release sounded like a 'slam dunk' but now all is for not. The zone that is producing is known to be prolfici but waters out quickly (probably why they tested such a small interval). It may payout the well costs but hardly a 'company maker'. Looks like this one is headed for the skids.

We need to get the TSX involved here as it seems like a misrepresentation of the facts.

Why say that fresh water is the problem - everyone knows Colombia is full of fresh water? They should have qualified their previous press release by disclosing the 'fresh water' risk factor. A lot of people got burnt here.

Let's see of the insiders sold off

i agree 100%, they made it sound like a slam dunk, they should have disclosed the risk.

and obviously by the day before trading if not several days before, demonstrates someone new it was going to be bad news.
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities